Hunan Jiudian Pharmaceutical Toekomstige groei

Future criteriumcontroles 4/6

Hunan Jiudian Pharmaceutical zal naar verwachting groeien in winst en omzet met respectievelijk 25.5% en 18.1% per jaar. De winst per aandeel zal naar verwachting groeien met 25.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 24.4% zijn.

Belangrijke informatie

25.5%

Groei van de winst

25.2%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	18.8%
Inkomstengroei	18.1%
Toekomstig rendement op eigen vermogen	24.4%
Dekking van analisten	Good
Laatst bijgewerkt	06 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Do Hunan Jiudian Pharmaceutical's (SZSE:300705) Earnings Warrant Your Attention?

Oct 22

With Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) It Looks Like You'll Get What You Pay For

Aug 12

Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Can Manage Its Debt Responsibly

Jun 23

Hunan Jiudian Pharmaceutical (SZSE:300705) Is Increasing Its Dividend To CN¥0.321

May 21

Here's Why We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Might Deserve Your Attention Today

Apr 12

Earnings Not Telling The Story For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) After Shares Rise 27%

Mar 04

Winst- en omzetgroeiprognoses

SZSE:300705 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	4,436	874	542	887	6
12/31/2025	3,750	673	369	634	7
12/31/2024	3,162	521	279	623	7
9/30/2024	2,945	508	235	646	N/A
6/30/2024	2,841	455	286	652	N/A
3/31/2024	2,782	417	192	571	N/A
12/31/2023	2,693	368	4	431	N/A
9/30/2023	2,620	371	60	490	N/A
6/30/2023	2,513	338	-86	427	N/A
3/31/2023	2,379	291	-162	369	N/A
1/1/2023	2,326	270	-144	269	N/A
9/30/2022	2,097	243	-55	262	N/A
6/30/2022	1,927	221	-16	163	N/A
3/31/2022	1,799	214	57	176	N/A
1/1/2022	1,628	204	65	191	N/A
9/30/2021	1,451	196	41	149	N/A
6/30/2021	1,317	162	48	166	N/A
3/31/2021	1,096	122	63	148	N/A
12/31/2020	978	82	72	150	N/A
9/30/2020	921	72	83	183	N/A
6/30/2020	891	59	31	144	N/A
3/31/2020	906	52	-15	127	N/A
12/31/2019	924	55	-91	91	N/A
9/30/2019	900	65	-162	64	N/A
6/30/2019	867	73	-176	62	N/A
3/31/2019	811	70	-200	76	N/A
12/31/2018	801	72	-189	68	N/A
9/30/2018	746	67	-160	40	N/A
6/30/2018	680	72	N/A	65	N/A
3/31/2018	613	71	N/A	56	N/A
12/31/2017	535	69	N/A	80	N/A
9/30/2017	472	72	N/A	86	N/A
6/30/2017	430	62	N/A	75	N/A
3/31/2017	385	56	N/A	52	N/A
12/31/2016	376	55	N/A	55	N/A
9/30/2016	334	39	N/A	35	N/A
6/30/2016	320	38	N/A	32	N/A
3/31/2016	305	41	N/A	32	N/A
12/31/2015	290	45	N/A	32	N/A
9/30/2015	281	43	N/A	30	N/A
6/30/2015	272	40	N/A	28	N/A
3/31/2015	269	41	N/A	34	N/A
12/31/2014	266	41	N/A	40	N/A
12/31/2013	241	36	N/A	31	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 300705 ( 25.5% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 300705 ( 25.5% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 26.2% per jaar).

Hoge groeiwinsten: De winst van 300705 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 300705 ( 18.1% per jaar) zal naar verwachting sneller groeien dan de markt CN ( 13.9% per jaar).

Hoge groei-inkomsten: De omzet van 300705 ( 18.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 300705 zal naar verwachting over 3 jaar hoog zijn ( 24.4 %)

Hunan Jiudian Pharmaceutical Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.23 in 3Q 2023)

Do Hunan Jiudian Pharmaceutical's (SZSE:300705) Earnings Warrant Your Attention?

Investor sentiment improves as stock rises 27%

New minor risk - Share price stability

Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.26 in 2Q 2023)

With Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) It Looks Like You'll Get What You Pay For

Investor sentiment deteriorates as stock falls 17%

Hunan Jiudian Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Can Manage Its Debt Responsibly

Investor sentiment deteriorates as stock falls 31%

Hunan Jiudian Pharmaceutical (SZSE:300705) Is Increasing Its Dividend To CN¥0.321

Dividend increased to CN¥0.32

Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023

Hunan Jiudian Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.22 in 1Q 2023)

Here's Why We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Might Deserve Your Attention Today

Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Earnings Not Telling The Story For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) After Shares Rise 27%

Investor sentiment improves as stock rises 19%

Hunan Jiudian Pharmaceutical Co., Ltd. Elects Yang Yang and Fan Pengyun as Non-Independent Director

Hunan Jiudian Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.24 in 3Q 2022)

Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings released: EPS: CN¥0.36 (vs CN¥0.22 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Hunan Jiudian Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 16, 2023

Hunan Jiudian Pharmaceutical Co., Ltd. Approves 2022 Final Profit Distribution, Payable on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.17 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.20 in 2Q 2021)

Hunan Jiudian Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 27 May 2022

Hunan Jiudian Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021

Investor sentiment improved over the past week

Nan Jiudian Pharmaceutical Announces Profit Distribution Plan for 2021

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.097 in 3Q 2020)

Investor sentiment deteriorated over the past week

Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) entered into an agreement to acquire Hunan Huiyang Information Technology Co., Ltd. from Duan Lixin and Duan Linong for CNY 8.56 million.

Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.11 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.35 (vs CN¥0.23 in FY 2019)

Hunan Jiudian Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 17, 2021

Full year 2020 earnings released: EPS CN¥0.34 (vs CN¥0.23 in FY 2019)

New 90-day high: CN¥28.81

New 90-day high: CN¥25.00

Third quarter earnings released

New 90-day high - CN¥20.99

Earnings released

Hunan Jiudian Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 22, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven